India’s top drug regulator, the Central Drugs Standard Control Organization (CDSCO), has stepped up its action against the misuse and illegal sale of GLP-1 drugs based weight-loss medicine across the country.

GLP-1 drugs, commonly used for diabetes and now increasingly popular for weight loss, are meant to be sold only on a valid doctor’s prescription. However, authorities have noticed that these medicines are being easily accessed through pharmacies, online platforms, wholesalers, and even slimming clinics—often without proper medical guidance.

Why the crackdown?

The increased availability of generic versions of these drugs has made them more accessible. This has raised concerns among health officials about misuse, self-medication, and unsafe consumption.

To address this, the CDSCO, along with state drug regulators, carried out inspections at 49 locations. These included online pharmacy warehouses, retail shops, wholesalers, and wellness clinics. The inspections focused on:

• Sale without valid prescription
• Improper prescribing practices
• Misleading promotions and advertisements

Several entities found violating the rules have already been issued notices.

Strict warning on promotions

Earlier, on March 10, the regulator also issued an advisory to drug manufacturers. It clearly banned:

• Surrogate advertising
• Indirect or misleading promotion
• Off-label promotion of GLP-1 drugs

This move aims to prevent companies from promoting these medicines as quick weight-loss solutions without highlighting the risks.

Who can prescribe these drugs?

Officials clarified that GLP-1 drugs should only be prescribed by qualified specialists such as:

• Endocrinologists
• Internal medicine doctors
• Cardiologists (for specific conditions)

Health risks of misuse

Medical experts have warned that using these drugs without proper supervision can lead to serious side effects and complications. These may include gastrointestinal issues, metabolic disturbances, and other long-term health risks.

What happens next?

The regulator has made it clear that patient safety is the top priority. Surveillance will continue in the coming weeks, and strict action will be taken against violators. This could include:

• Cancellation of licenses
• Financial penalties
• Legal prosecution

The move sends a strong message to the pharmaceutical supply chain: prescription drugs cannot be treated as over-the-counter products, especially when they carry significant health risks.

For more updates on medical students, follow us on X (Twitter), Instagram & Facebook. And our website MED COLLEGE DARSHAN.